BR112017014953A2 - microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos - Google Patents

microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos

Info

Publication number
BR112017014953A2
BR112017014953A2 BR112017014953A BR112017014953A BR112017014953A2 BR 112017014953 A2 BR112017014953 A2 BR 112017014953A2 BR 112017014953 A BR112017014953 A BR 112017014953A BR 112017014953 A BR112017014953 A BR 112017014953A BR 112017014953 A2 BR112017014953 A2 BR 112017014953A2
Authority
BR
Brazil
Prior art keywords
active ingredient
microglobules
core
producing
layers
Prior art date
Application number
BR112017014953A
Other languages
English (en)
Inventor
Niichel Robert
Original Assignee
Nano Pharmaceutical Laboratories Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nano Pharmaceutical Laboratories Llc filed Critical Nano Pharmaceutical Laboratories Llc
Publication of BR112017014953A2 publication Critical patent/BR112017014953A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

um microglóbulo em camadas adequado para incorporar um produto consumível sem prescrição é divulgado. o microglóbulo em camadas pode incluir um núcleo e pelo menos uma camada de ingrediente ativo que envolve o núcleo. o ingrediente ativo no núcleo pode ser diferente do ingrediente ativo na camada de encapsulação. o ingrediente ativo no núcleo pode ser selecionado para neutralizar ou intensificar o efeito do ingrediente ativo na camada de encapsulação. o microglóbulo em camadas pode ainda incorporar microesferas de ingrediente ativo cercadas por material polimérico. o método de produção de microesferas e microglóbulos também é descrito.
BR112017014953A 2015-01-12 2015-06-05 microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos BR112017014953A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102477P 2015-01-12 2015-01-12
US201562150181P 2015-04-20 2015-04-20
PCT/US2015/034571 WO2016114812A1 (en) 2015-01-12 2015-06-05 Layered sustained-release microbeads and methods of making the same

Publications (1)

Publication Number Publication Date
BR112017014953A2 true BR112017014953A2 (pt) 2018-03-13

Family

ID=56366743

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014953A BR112017014953A2 (pt) 2015-01-12 2015-06-05 microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos

Country Status (7)

Country Link
US (3) US9931344B2 (pt)
EP (1) EP3244881A4 (pt)
JP (1) JP2018504454A (pt)
AU (1) AU2015377223A1 (pt)
BR (1) BR112017014953A2 (pt)
CA (1) CA2978593A1 (pt)
WO (1) WO2016114812A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3244881A4 (en) 2015-01-12 2018-08-15 Nano Pharmaceutical Laboratories LLC Layered sustained-release microbeads and methods of making the same
JP6925014B2 (ja) * 2017-02-15 2021-08-25 ドリームメディカルパートナーズ株式会社 塞栓材の製造方法
AU2019288476A1 (en) * 2018-06-21 2021-03-18 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
EP3622948A1 (en) 2018-09-11 2020-03-18 I.P.S. International Products & Services S.r.l. Multilayered formulations with dual release rate of one or more active principles
US11793753B2 (en) 2019-09-12 2023-10-24 Nulixir Inc. Methods and systems for forming layered solid particles
WO2023043854A1 (en) * 2021-09-14 2023-03-23 Nulixir Inc. Alimentary-related particles, production methods, and production apparatus
WO2023214280A1 (en) * 2022-05-06 2023-11-09 Craft Health Pte Ltd System for controllable release in 3d-printed colon targeting (corr3ct) oral dosage form

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182778A (en) 1978-05-17 1980-01-08 General Foods Corporation Encapsulation of vitamin and mineral nutrients
WO1983003061A1 (en) 1982-03-04 1983-09-15 Battelle Development Corp Dual microcapsules
US4717713A (en) 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
US5296236A (en) 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5728403A (en) 1994-10-05 1998-03-17 The Board Of Regents Of The University Of Nebraska Coating technology for taste masking orally administered bitter drugs
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
CA2267116A1 (en) 1996-10-09 1998-04-16 Givaudan-Roure (International) S.A. Process for preparing beads as food additive
PT946145E (pt) 1996-12-20 2008-10-17 Mcneil Ppc Inc Fármacos antitússicos libertados por resinas de troca iónica
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2277407A1 (en) * 1999-07-14 2001-01-14 Bernard Charles Sherman Pharmaceutical tablet comprising an nsaid and misoprostol
US6458384B2 (en) 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6451808B1 (en) * 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
CN1674786A (zh) 2002-08-14 2005-09-28 纳幕尔杜邦公司 经涂布的含多不饱和脂肪酸的颗粒以及经涂布的含液体药物的颗粒
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2005025570A1 (en) 2003-09-15 2005-03-24 Diamedica Inc. Use of antagonists of hepatic sympathetic nerve activity
EP1727520A2 (en) 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP2008507504A (ja) 2004-07-22 2008-03-13 ファイザー・プロダクツ・インク 溶解遅延形態の薬物及び／又は溶解増進形態のシクロデキストリンを含む味マスキング製剤
US7229690B2 (en) 2004-07-26 2007-06-12 Massachusetts Institute Of Technology Microspheres including nanoparticles
US20080107789A1 (en) 2004-12-06 2008-05-08 Asahi Kasei Chemicals Corporation Composition composed of highly dispersible cellulose complex and polysaccharide
EP1879583A2 (en) 2005-05-03 2008-01-23 Mutual Pharmaceutical Company, Inc. Quinine formulations
US20110064803A1 (en) 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US7851005B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
JP5457830B2 (ja) * 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
WO2008048469A2 (en) * 2006-10-13 2008-04-24 Actavis Group Pct Hf Controlled-release coated dosage forms containing galantamine
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
US10933024B2 (en) * 2008-09-24 2021-03-02 Evonik Operations Gmbh PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
EP2355660A4 (en) 2008-10-13 2012-05-02 Biovista Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
US20120034302A1 (en) 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
EP3244881A4 (en) 2015-01-12 2018-08-15 Nano Pharmaceutical Laboratories LLC Layered sustained-release microbeads and methods of making the same

Also Published As

Publication number Publication date
US10512650B2 (en) 2019-12-24
AU2015377223A1 (en) 2017-08-31
CA2978593A1 (en) 2016-07-21
US20200276202A1 (en) 2020-09-03
JP2018504454A (ja) 2018-02-15
EP3244881A1 (en) 2017-11-22
WO2016114812A1 (en) 2016-07-21
EP3244881A4 (en) 2018-08-15
US9931344B2 (en) 2018-04-03
US20180369248A1 (en) 2018-12-27
US20160199378A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
BR112017014953A2 (pt) microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos
EP3753540A3 (en) Articles comprising an absorbent core and methods of making
CL2017000288A1 (es) Encapsulación de compuestos hidrofóbicos biologicamente activos
CL2020002269A1 (es) Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433)
EP3552495A4 (en) OIL-IN-WATER EMULSION COMPOSITION AND METHOD FOR PRODUCING THE OIL-IN-WATER EMULSION COMPOSITION
GB2537545A (en) Penetration barrier for additive manufacturing
SG11201709383UA (en) Oil-in-water type emulsion composition and method for producing same
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
EP4233889A3 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
EA201700209A1 (ru) Частицы для высвобождения активных ингредиентов
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
BR112018008995A8 (pt) processo para fabricar um filme multicamadas, processo para fabricar um filme não respirável multicamadas, filme multicamadas, filme não respirável multicamadas, filme parcialmente respirável multicamadas e produto de higiene pessoal
WO2014111811A8 (en) Veterinary supplements
BR112017012932A2 (pt) emulsão, processo de preparação de emulsão, uso das partículas compostas e processo de tratamento cosmético de material queratínico
BR112016025876A8 (pt) composição, processos para preparar uma microcápsula e uma forma de dosagem unitária, forma de dosagem unitária, microcápsula, produto, uso de uma composição, e, método para tratar uma condição associada à vitamina k1 ou k2
BR112018003578A2 (pt) composições de óleo refinado e métodos para fazer
EP3492476A4 (en) SULPHONIUM SALT, HEAT OR PHOTO ACID GENERATOR, HEAT-CURABLE OR PHOTO-CURABLE COMPOSITION AND HARDENED PRODUCT THEREOF
WO2017098003A3 (de) Verfahren und vorrichtung zur prüfung eines eingangsdatensatzes einer generativen schichtbauvorrichtung
MX2019012446A (es) Beta-caseina a2 y reduccion y prevencion de sintomas de intolerancia a la lactosa.
EP3359470A4 (en) PRODUCT PACKAGING WITH ODOR PREVENTION AND METHOD FOR FORMING THEREOF
BR112017000047A2 (pt) método estereolitográfico, dispositivo e produto de programa de computaor para produção de objeto tridimensional
PH12015501013A1 (en) Bar soap composition and method of manufacture
BR112016029507A2 (pt) ?embalagem, material de acondicionamento, e, método de fabricação de um material de acondicionamento?
AR101390A1 (es) Composición alimenticia recubierta para animales y método para producirla

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired